Join
Live feed
·
INSIDERFilingvia Quantisnow
Xenon Pharmaceuticals Inc. logo

Director Cannon Gillian sold $63,237 worth of shares (1,190 units at $53.14) as part of a pre-agreed trading plan, decreasing direct ownership by 45% to 1,455 units (SEC Form 4) to satisfy tax liability

ByQuantisnow·Wall Street's wire, on your screen.
XENE· Xenon Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XENE (Xenon Pharmaceuticals Inc.) and more on Quantisnow.